Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate vs Oral Antipsychotics in Schizophrenia
NCT01193166Phase 4Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2010
- Primary completion
- Sep 2012
- Modality
- Metabolically Activated Prodrugs
01
Overview
A Phase 4 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Planned start Aug 2010; status: withdrawn.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01193166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193166.